BioGend Therapeutics Co., Ltd.

TPEX:6733 Stock Report

Market Cap: NT$4.8b

BioGend Therapeutics Valuation

Is 6733 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6733 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6733's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6733's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6733?

Other financial metrics that can be useful for relative valuation.

6733 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue31.2x
Enterprise Value/EBITDA-40.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 6733's PS Ratio compare to its peers?

The above table shows the PS ratio for 6733 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average22.1x
6875 Pharmosa Biopharm
24.4xn/aNT$7.9b
6808 3D Global Biotech
53.4xn/aNT$2.9b
1783 Maxigen Biotech
6.2xn/aNT$3.7b
4169 TCM Biotech International
4.3xn/aNT$3.6b
6733 BioGend Therapeutics
36x30.6%NT$4.8b

Price-To-Sales vs Peers: 6733 is expensive based on its Price-To-Sales Ratio (36x) compared to the peer average (22.1x).


Price to Earnings Ratio vs Industry

How does 6733's PE Ratio compare vs other companies in the TW Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a48.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a48.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 6733 is expensive based on its Price-To-Sales Ratio (36x) compared to the TW Biotechs industry average (23.3x).


Price to Sales Ratio vs Fair Ratio

What is 6733's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6733 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio36x
Fair PS Ratio16.8x

Price-To-Sales vs Fair Ratio: 6733 is expensive based on its Price-To-Sales Ratio (36x) compared to the estimated Fair Price-To-Sales Ratio (16.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies